期刊文献+

Involvement of MMP-2 in Adriamycin Resistance Dependent on ERK1/2 Signal Pathway in Human Osteosarcoma MG-63 Cells 被引量:2

Involvement of MMP-2 in Adriamycin Resistance Dependent on ERK1/2 Signal Pathway in Human Osteosarcoma MG-63 Cells
下载PDF
导出
摘要 Matrix metalloproteinase-2 (MMP-2) level and the ERK1/2 signal pathway are dependent factors for the growth and metastasis of cancer.However,the impact of MMP-2 in combination with ERK1/2 in tumor patients with drug resistance is unknown.To determine the relationship between MMP-2 and the ERK1/2 signal pathway,we established an adriamycin (ADM)-induced MG-63 (ADM-MG-63) cell line.With the increase of the ERK1/2 pathway blocker PD98059,we detected the expression levels of MMP-2 and p-ERK1/2 by Western blot in ADM-MG-63 cells.In ADM-MG-63 cells transfected with MMP-2-siRNA,the expression of ERK1/2 was detected for understanding the function of the ERK1/2 signal pathway.Three siRNAs for MMP-2 (MMP-2-siRNA) were designed,and the optimal one was selected and tested at different time points of 24,48 and 72 h.Under an ADM-induced condition,ADM-MG-63 cells were finally stable living in the medium of ADM (200 ng/mL).PD98059 could effectively suppress the expression levels of p-ERK1/2 and MMP-2.When the MMP-2 was silenced by using MMP-2-siRNA,the expression of p-ERK1/2 was enhanced.It is con-cluded that MMP-2 may be involved in ADM resistance dependent on ERK1/2 signal pathway,sug-gesting interference in ERK1/2 may be a new method of targeted therapy for tumor resistance. Matrix metalloproteinase-2 (MMP-2) level and the ERK1/2 signal pathway are dependent factors for the growth and metastasis of cancer.However,the impact of MMP-2 in combination with ERK1/2 in tumor patients with drug resistance is unknown.To determine the relationship between MMP-2 and the ERK1/2 signal pathway,we established an adriamycin (ADM)-induced MG-63 (ADM-MG-63) cell line.With the increase of the ERK1/2 pathway blocker PD98059,we detected the expression levels of MMP-2 and p-ERK1/2 by Western blot in ADM-MG-63 cells.In ADM-MG-63 cells transfected with MMP-2-siRNA,the expression of ERK1/2 was detected for understanding the function of the ERK1/2 signal pathway.Three siRNAs for MMP-2 (MMP-2-siRNA) were designed,and the optimal one was selected and tested at different time points of 24,48 and 72 h.Under an ADM-induced condition,ADM-MG-63 cells were finally stable living in the medium of ADM (200 ng/mL).PD98059 could effectively suppress the expression levels of p-ERK1/2 and MMP-2.When the MMP-2 was silenced by using MMP-2-siRNA,the expression of p-ERK1/2 was enhanced.It is con-cluded that MMP-2 may be involved in ADM resistance dependent on ERK1/2 signal pathway,sug-gesting interference in ERK1/2 may be a new method of targeted therapy for tumor resistance.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2012年第1期82-86,共5页 华中科技大学学报(医学英德文版)
基金 supported by a grant from the Major State Basic Research Development of China (No. 2002CB513107)
关键词 ADRIAMYCIN matrix metalloproteinase-2 OSTEOSARCOMA RNA interference adriamycin matrix metalloproteinase-2 osteosarcoma RNA interference
  • 相关文献

参考文献18

  • 1Marina N,Gebhardt M,Teot L. Biology and therapeutic advances for pediatric osteosarcoma[J].Oncologist(The),2004,(04):422-441.
  • 2Cleton-Jansen AM,Anninga JK,Briaire-de Bruijn IH. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways[J].British Journal of Cancer,2009,(11):1909-1918.
  • 3Matsubara H,Watanabe M,Imai T. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228[(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetra azabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone][J].Journal of Pharmacology and Experimental Therapeutics,2009,(03):839-848.
  • 4Hirotsu M,Setoguchi T,Sasaki H. Smoothened as a new therapeutic target for human osteosarcoma[J].Molecular Cancer Therapeutics,2010.5-19.
  • 5Susa M,Iyer AK,Ryu K. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J].BMC Cancer,2009.399-411.
  • 6Sakamoto A,Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma:chemotherapy[J].Rev Recent Clin Trials,2008,(03):228-231.
  • 7Adya R,Tan BK,Punn A. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signaling pathways:novel insights into visfatin-inducedangiogenesis[J].Cardiovascular Research,2008,(02):356-365.
  • 8Séguin CA,Pilliar RM,Madri JA. TNF-alpha induces MMP2 gelatinase activity and MT1-MMP expression in an in vitro model of nucleus pulposus tissue degeneration[J].Spine,2008,(04):356-365.
  • 9Steelman LS,Pohnert SC,Shelton JG. JAK/STAT,Raf/MEK/ERK,PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2004,(02):189-218.
  • 10Overall CM,Kleifeld O. Tumour microenvironment-opinion:validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy[J].Nature Reviews Cancer,2006,(03):227-239.

同被引文献6

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部